UnknownPhase 1NCT05354089

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Principal Investigator
Lanjuan Li
Shulan (Hangzhou) Hospital
Intervention
20 μg dose of SYS6006(biological)
Enrollment
40 target
Eligibility
18-59 years · All sexes
Timeline
20222023

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05354089 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials